What are the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy: a prospective single-centre study in China

Hong-Li Liu,¹ Jia-Jia Yuan,¹ Zhen Tian,² Xin Li,² Lin Song,¹ Bin Li¹²

ABSTRACT

Objective To study the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy.

Design Prospective study.

Setting 3-A-class hospital in China; single-centre study.

Participants From 100 patients diagnosed with Leber hereditary optic neuropathy, 80 (160 eyes; 68 men and 12 women; youngest patient, 6 years; oldest patient, 35 years) were recruited.

Exposure All patients were followed up for at least 12 months. Each patient underwent at least three visual field examinations. Patient groups 1–6 were created according to the time of visual field data acquisition. Patient group 7 included patients with a different onset of disease between eyes. Group 8 was composed of patients with a course of disease of 12–24 months when one of the examinations performed. Patients who performed the third examination made up patient group 9.

Primary outcome measures Prevalence of the different visual field defect types on the basis of severity in groups 1–6. Mean of the difference of visual function between eyes in group 7.

Result In groups 1–6, the prevalences of defects classified using Visual Field Index values were significantly different between groups 1 and 3. In group 7, with the prolongation of the course of the disease, the differences in visual function between eyes decreased. There was no significant correlation between age and the severity of visual field defect. There was significant correlation between visual acuity and the severity of visual field defect.

Conclusion Visual field defects in patients with Leber hereditary optic neuropathy (G11778A) may continuously progress within 6 months of disease development, and remain stable after 9 months. With the progression of the disease, the differences in visual function between eyes may decrease. The severity of visual field defect seems to be independent of age; however, could be related to visual acuity.

Trial registration number NCT03428178, NCT01267422.

INTRODUCTION

Leber hereditary optic neuropathy (LHON) is an inherited mitochondrial disease characterised by bilateral, (sub) acute, painless vision loss. The G11778A mitochondrial DNA point mutation is most commonly associated with LHON.¹² Our study group and other researchers are conducting clinical trials to assess the safety and efficacy of gene therapy for LHON.³⁴ However, during the course of gene therapy for LHON, we found that determination of the optimal time window for treatment is very important.

Visual field examination is an important procedure for diagnosis, gene therapy, evaluation of treatment efficacy and follow-up observation in patients with LHON. In a previous study, we analysed the characteristics of different types of visual field defects in 32 patients with LHON; however, the number of patients was small and detailed grading had not been possible.

In the present study, we used the semiquantitative visual field classification methods applied for patients with glaucoma based
on Visual Field Index (VFI) and mean deviation (MD) values to ensure thorough analysis of the relationship between the severity of visual field defects and the disease course. In addition, the characteristics of visual function in patients with a different onset of disease between eyes, and the relationship between the severity of visual field defect and age or visual acuity were analysed in detail. We used visual field data acquired at different points of time after vision loss to evaluate the characteristics and progression of visual field defects in patients with LHON and determine the optimal time window for treatment.

**METHODS**

**Study subjects**

In total, 160 eyes of 80 sporadic patients diagnosed with LHON (gene sequencing showed MTND4m.11778 G>A) between December 2016 and December 2017 were recruited for this study. All patients were followed up for at least 12 months, during which they underwent at least three visual field examinations. Inclusion criteria included: compliance with LHON diagnostic criteria (the symptoms and signs of patients were consistent with the clinical manifestations of LHON. Meanwhile, genetic testing showed MTND4m.11778 G>A); provided informed consent; voluntary participation; ≥60 years old; the time of referral. Exclusion criteria were: severe cardiopulmonary and renal dysfunction, cancer, bleeding disorders, acute infectious disease, high fever, high fever disease, pregnancy, heart disease and patients with mental disorders.

**Patient groups**

According to previous literature reports and clinical findings, the first 6 months after disease development constitute the acute or progressive phase, whereas the following 6 months constitute the chronic or optic nerve atrophy phase. At 1 year after disease development, the status of the visual field stabilises. Therefore, we created groups 1–6 according to the time of visual field data acquisition after vision loss: group 1, visual field data obtained within 1 month; group 2, visual field data obtained between 1 and 3 months; group 3, visual field data obtained between 3 and 6 months; group 4, visual field data obtained between 6 and 9 months; group 5, visual field data obtained between 9 and 12 months; and group 6, visual field data obtained between 12 and 24 months. All patients with a different onset of disease between eyes were included in patient group 7. Patient group 7 was divided into six subgroups according to the time of visual field data acquisition after vision loss: subgroup 1, visual field data obtained within 1 month; subgroup 2, visual field data obtained between 1 and 3 months; subgroup 3, visual field data obtained between 3 and 6 months; subgroup 4, visual field data obtained between 6 and 9 months; subgroup 5, visual field data obtained between 9 and 12 months; and subgroup 6, visual field data obtained between 12 and 24 months. Patient group 8 was composed of the patients with a course of disease of 12–24 months when one of the examinations performed. Patients who performed the third examination made up patients group 9.

**Visual field examination**

The 30-2 SITA-FAST program (HFAII740: Humphrey Field Analyzer II, Carl Zeiss Meditec, Dublin, California, USA) was used for standard automatic visual field examination of all participants. Under the guidance of an experienced physician, each subject underwent BCVA examination. Visual field testing is performed with vision correction in a dark room. A practice examination before the actual one was required for subjects undergoing visual field testing for the first time. Pupil dilation was performed for subjects with a pupil diameter <2.5 mm. The following parameters were used to inhibit mydriasis: stimulus cursor, III, white; stimulus cursor duration, 200 ms; background light intensity, 31.5 apostilb (ASB); and stimulus cursor intensity, 0.08–10 000 ASB.

The following parameters were recorded for all patients: fixation loss, false-positive rate, false-negative rate, MD, pattern SD and VFI. Patients with a fixation loss of >20% and a false-positive or false-negative rate of >15% were excluded.

**Classification of visual field defects**

Two trained evaluators classified the visual field defects according to VFI and MD values. A third trained evaluator made a decision in case of any disagreement between the two evaluators.

**Classification based on VFI**

The visual field defects were classified according to the University of São Paulo Glaucoma Visual Field Staging System (USP-GVFSS): early defect, VFI >91%; intermediate defect, 78% < VFI ≤ 91% and severe defect, VFI ≤ 78%.

**Classification based on MD**

The visual field defects were classified according to the Hodapp-Parrish-Anderson system (HPA): early defect, −6.00 dB < MD ≤ −0.01 dB, when the defect degree (P) ≤ 5%, it is less than 18 points on the pattern deviation probability plots, or when p≤1%, it is less than 10 points; moderate defect, −12.00 dB < MD ≤ −6.01 dB,
when \( p < 5\% \), \( p < 37 \) points or when \( p < 1\% \), \( p < 20 \) points; and severe defect, \( MD < \pm 12.01 \) dB, when \( p < 5\% \), \( p \geq 37 \) points or when \( p < 1\% \), \( p \geq 20 \) points.

**Statistical analysis**

All data are expressed as mean±SD. All statistical analyses were carried out using IBM SPSS statistics (SPSS V.22.0, SPSS Science). In patient groups 1–6, the ranked data non-parametric test was used for comparisons among multiple groups; a \( p < 0.05 \) was considered statistically significant. While the multiple comparisons test was used for comparison between two groups, a corrected \( p < 0.005 \) was considered statistically significant. In patient group 7, the mean of the difference values of VFI/MD between eyes in each subgroup was calculated. In patient groups 8 and 9, linear correlation tests were used to analyse the relationship between age or visual acuity and VFI/MD values.

**Patient and public involvement**

Patients were involved in setting the research question and in the design of the study. During the feasibility stage, the priority of the research question, choice of outcome measures and methods of recruitment were informed by discussions with patients through in-person interviews and telephone surveys. No patients were asked for advice on the interpretation or writing up of results. The results of the research have been disseminated to the patient community through emails.

**RESULTS**

From 100 patients whose gene sequencing showed MTND4m.11778 G>A, in total, 160 eyes of 80 patients who underwent their first examination within 2 years of disease development were recruited for the three examinations. There were 68 men and 12 women, with the youngest patient aged 6 years and the oldest, aged 35 years.

**Classification of visual field defects**

After the exclusion of 17 patients lost to follow-up and the elimination of inaccurate data (according to reliability index of visual field data and the course of the disease), 271 visual field data were divided into six groups ultimately. Of the total data, 39 were included in group 1, 45 in group 2, 60 in group 3, 49 in group 4, 40 in group 5 and 38 in group 6.

The classification of visual field defects according to MD and VFI values in each group is shown in table 1. There was a significant difference in the prevalence of the different defect types based on severity among multiple groups (\( p_{VFI} = 0.002 \leq 0.05 \), \( p_{MD} = 0.001 \leq 0.05 \)). When VFI was used for classification, there was a significant difference between groups 1 and 3 (\( p = 0.001 \leq 0.005 \)), with no significant difference between adjacent groups. When MD was used for classification, there was a significant difference between groups 1 and 4 (\( p = 0.000 \leq 0.005 \)), with no significant difference between adjacent groups (figure 1).

**Characteristics of visual field defect between eyes**

In total, 33 patients were included in group 7, with the maximum and minimum interval times of 33 months and 1 month, respectively. Eight data were included in subgroup 1, 8 in subgroup 2, 14 in subgroup 3, 13 in subgroup 4, 14 in subgroup 5, 16 in subgroup 6.

Mean of the difference of visual function between eyes according to MD and VFI values in each subgroup is shown in table 2. From subgroup 1 to subgroup 6, the mean of the difference based on VFI or MD values between eyes decreased (figure 2).

**Table 1**

Classification of visual field defects according to the mean deviation (MD) and Visual Field Index (VFI) values for patients with Leber hereditary optic neuropathy stratified into groups according to the time course of the disease

| Classification of visual field defect | Type | Group 1, % | Group 2, % | Group 3, % | Group 4, % | Group 5, % | Group 6, % |
|-------------------------------------|------|-----------|-----------|-----------|-----------|-----------|-----------|
| VFI                                 | 1    | 11.11     | 4.88      | 2.00      | 0         | 0         | 0         |
|                                     | 2    | 22.22     | 14.63     | 4.00      | 8.16      | 10.00     | 7.89      |
|                                     | 3    | 66.67     | 80.49     | 94.00     | 91.84     | 90.00     | 92.11     |
| MD                                  | 1    | 17.95     | 8.89      | 4.44      | 2.04      | 2.50      | 2.63      |
|                                     | 2    | 28.21     | 17.78     | 20.00     | 10.20     | 17.50     | 7.89      |
|                                     | 3    | 53.85     | 73.33     | 75.56     | 87.76     | 80.00     | 89.47     |

1: Early visual field defect.
2: Moderate/intermediate visual field defect.
3: Severe visual field defect.

Group 1: visual field data obtained within 1 month after vision loss.
Group 2: visual field data obtained between 1 and 3 months after vision loss.
Group 3: visual field data obtained between 3 and 6 months after vision loss.
Group 4: visual field data obtained between 6 and 9 months after vision loss.
Group 5: visual field data obtained between 9 and 12 months after vision loss.
Group 6: visual field data obtained between 12 and 24 months after vision loss.
Forty-two patients comprised the patient group 8, with the youngest patient aged 11 years and the oldest, aged 35 years. There was no significant correlation between the VFI or MD values and ages in patient group 8 (p(VFI)=0.132>0.05, p(MD)=0.199>0.05).

Correlation between visual acuity and visual field
Patient group 9 was composed of 66 patients. There were significant correlations among the changes in the VFI and BCVA (r(VFI)=−0.629, p(VFI)=0.000≤0.05, r(MD)=−0.640, p(MD)=0.000≤0.05).

DISCUSSION
Based on the clinical characteristics of LHON (G11778A), the patient loses vision rapidly, even in a few days. However, visual field defects continuously progress to a stable state. How do the visual field defects progress? In this study, we found that the two classification methods yielded similar results. The magnitude of progression in adjacent 1-month and 1–3 months periods was not enough to yield a statistically significant difference, and there were no significant differences among the groups beyond 9 months. Thus, it appears that visual field defects continuously and rapidly progressed within the first 6 months after disease development and after 9 months, the defects had progressed to a stable state. This conclusion based on statistical analyses also matches that based on our longitudinal observations of obvious visual field defect progression at 1, 3 and 6 months in most patients, followed by stabilisation of the visual field at 6, 9 and 12 months. From the perspective of clinical significance, the severity of visual field defects reflects visual function, namely retinal ganglion cell (RGC) function, and it can be inferred that the number of RGCs rapidly decreases in the first 6 months after disease development and generally stabilises after 9 months, with stabilisation of RGC function between 6 and 9 months.

This disease progression pattern coincides with the findings of comprehensive visual electrophysiology for patients with LHON in a study by Majander A et al,11 and the findings in nerve fibres in a study by Nikoskelainen et al.12 It also corresponds to the previous staging system for LHON, where in the first 6 months following disease development constitute the acute or progressive phase and the next 6 months constitute the chronic or optic nerve

| Subgroup | VFI   | MD    |
|----------|-------|-------|
| 1        | 41.00 | 12.07 |
| 2        | 16.00 | 5.33  |
| 3        | 16.77 | 5.82  |
| 4        | 8.86  | 2.70  |
| 5        | 9.00  | 3.53  |
| 6        | 10.56 | 3.57  |

Subgroup 1: visual field data obtained within 1 month after vision loss.
Subgroup 2: visual field data obtained between 1 and 3 months after vision loss.
Subgroup 3: visual field data obtained between 3 and 6 months after vision loss.
Subgroup 4: visual field data obtained between 6 and 9 months after vision loss.
Subgroup 5: visual field data obtained between 9 and 12 months after vision loss.
Subgroup 6: visual field data obtained between 12 and 24 months after vision loss.
with LHON, while Ran analysed the morphological characteristics of visual field defects in 32 patients with LHON. Newman et al. closely observed visual field defect progression from the early asymptomatic stage to complete vision loss as an endpoint in nine patients with LHON. However, the number of cases in these studies was small, and not all patients had the G11778A mutation, so an accurate classification of the severity of defects was not possible. For instance, LHON strikes first one eye and the second eye becomes involved within a 2–4 months period. How do the visual field defects progress in these patients? In our present study, we found that irrespective of the values (VFI or MD) used, mean of the difference between eyes decreased with the course of the disease. In other words, along with the progression of the disease, differences of visual function between eyes decreased in patients with different times of onset of the disease. In addition, we found the severity of visual field defect was independent of age, but related to visual acuity when the visual function remains stable.

The present study has some limitations. First, we examined the central 30° of the visual field in our patients. However, patients with LHON have visual field defects covering a wide area, most of which rapidly progress to severe diffuse defects. Second, the use of a single visual field calculation method could have yielded suboptimal measurements because of individual differences or compensatory effects between different pathways in the visual system.

Currently, gene therapy for LHON is safe and effective, but individual variations in the treatment efficacy are very large. Therefore, an optimal time window for gene therapy is of great significance. Previous studies have found that, in the early stages of LHON, the status of RGCs is unstable and nerve fibres are swollen. Balducci et al. proposed a time window of 6 months after disease development for gene therapy. From our studies, we conclude that RGCs are in a state of deterioration for the first 6 months after disease development and gradually stabilise at 6–9 months. Accordingly, we propose that gene therapy should be ideally performed within the first 6 months after disease development. In other words, gene therapy should be performed when visual field defects are in the progressive stage in order to mitigate optic nerve damage to the greatest extent and achieve better recovery and outcomes.

**CONCLUSION**

First, our findings suggest that visual field defects in patients with LHON (G11778A) may continuously progress within 6 months, tend to stabilise between 6 and 9 months, and remain stable after 9 months. Administration of gene therapy within 6 months of disease development could prevent progressive injury to the optic nerve. Second, along with the progression of the disease, differences of visual function between eyes decreased in patients with different times of onset of the disease. Third, the severity of visual field defects was not related to age, however, is correlated with visual acuity. The findings provide useful information for guiding gene therapy and developing a deeper understanding of LHON, particularly in terms of the disease course.

**Acknowledgements**  The authors thank all patients who have participated in this research for their kind cooperation.

**Contributors**  BL designed the experiments and obtained funding. H-LL and J-JY collected the data; LS performed the visual field examination. ZT and XL analysed the data. H-LL drafted the manuscript. All authors approved the final version of the manuscript.

**Funding**  This work was supported by the National Natural Science Foundation (Grant Number 81770969) of the People’s Republic of China.

**Competing interests**  None declared.

**Patient consent for publication**  Obtained.
Ethics approval The study was approved by the ethics committee of Tongji Hospital at the Tongji Medical College and was conducted in strict accordance with the regulations of the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011;30:81–114.
2. Yu-Wai-Man P, Votruba M, Burté F, et al. A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathol 2016;132:789–806.
3. Wan X, Pei H, Zhao MJ, et al. Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy. Sci Rep 2016;6:21587.
4. Guy J, Feuer WJ, Davis JL, et al. Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results. Ophthalmology 2017;124:1621–34.
5. Ran R, Yang S, He H, et al. A retrospective analysis of characteristics of visual field damage in patients with Leber’s hereditary optic neuropathy. Springerplus 2016;5:843.
6. Balducci N, Savini G, Cascavilla ML, et al. Macular nerve fibre and ganglion cell layer changes in acute Leber’s hereditary optic neuropathy. Br J Ophthalmol 2016;100:1232–7.
7. Yu-Wai-Man P, Griffiths PG, Hudson G, et al. Inherited mitochondrial optic neuropathies. J Med Genet 2009;46:145–58.
8. Wei QP, Sun YH, Zhou XT, et al. [A clinical study of Leber hereditary optic neuropathy]. Zhonghua Yan Ke Za Zhi 2012;48:1065.
9. Susanna R, Vessani RM. Staging glaucoma patient: why and how? Open Ophthalmol J 2009;3:59–64.
10. Hodapp E, Parrish R-K, Anderson D-R. Clinical decisions in glaucoma: Mosby, 1993.
11. Majander A, Robson AG, João C, et al. The pattern of retinal ganglion cell dysfunction in Leber hereditary optic neuropathy. Mitochondrion 2017;36:138–49.
12. Nikoskelainen E, Hoyt WF, Nummelin K. Ophthalmoscopic findings in Leber’s hereditary optic neuropathy. I. Fundus findings in asymptomatic family members. Arch Ophthalmol 1982;100:1597.
13. Wakakura M, Fujie W, Emoto Y. Initial temporal field defect in Leber hereditary optic neuropathy. Jpn J Ophthalmol 2009;53:603–7.
14. Newman NJ, Bloussé V, Newman SA, et al. Progression of visual field defects in leber hereditary optic neuropathy: experience of the LHON treatment trial. Am J Ophthalmol 2006;141:1061–7.
15. Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber’s hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 1991;111:750–62.